CytRx Corporation Announces Initial Results From Pharmacokinetics Clinical Trial With Aldoxorubicin in Solid Tumors

Published: May 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced initial data from a Phase 1b clinical trial evaluating the pharmacokinetics and safety of aldoxorubicin, its novel conjugate of the widely used chemotherapeutic agent doxorubicin, in patients with metastatic solid tumors who have either relapsed or not responded to treatment with standard therapies. The data indicate that aldoxorubicin has a distribution half-life of 20-24 hours following infusion, which is significantly longer than doxorubicin’s initial half-life of five minutes. The data also demonstrate that aldoxorubicin demonstrated a distribution to healthy tissues that was 250-fold lower than that of doxorubicin.

Help employers find you! Check out all the jobs and post your resume.

Back to news